Tier 2 — strong

Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study

Sergey Kozhukhov, Alexander Parkhomenko, Yaroslav Lutay, Nataliia Dovganych, Study Investigators
Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2024 76:68-74

Bibliography

PubMed
PMID 37567562
DOI
10.1016/j.hjc.2023.08.004
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized open-label multicenter pilot trial
ModelHuman intervention research
Sample143 adults with acute anterior STEMI; 70 intervention and 73 control
InterventionIntravenous quercetin plus standard reperfusion care versus standard care
DurationInfusions before reperfusion and over the following 5 days
EndpointsProtein activity, binding or signaling

What the study showed, in plain terms

Published in 2024, this source examined cardiovascular and metabolic health. Design: Randomized open-label multicenter pilot trial. Sample/model: 143 adults with acute anterior STEMI; 70 intervention and 73 control. The exposure or intervention was Intravenous quercetin plus standard reperfusion care versus standard care. Follow-up or treatment period: Infusions before reperfusion and over the following 5 days.

The intervention reduced enzyme-based infarct-size measures and intramyocardial hemorrhage. Ejection fraction and remodeling measures did not differ.

Hospital-based intravenous formulation and open-label pilot design. Findings cannot be transferred to oral supplement capsules.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • The intervention reduced enzyme-based infarct-size measures and intramyocardial hemorrhage.
  • Ejection fraction and remodeling measures did not differ.
  • The recorded outcome domains were Protein activity, binding or signaling.
  • The result applies to the tested exposure: Intravenous quercetin plus standard reperfusion care versus standard care; Infusions before reperfusion and over the following 5 days.

What this study can and cannot tell us

  • Hospital-based intravenous formulation and open-label pilot design. Findings cannot be transferred to oral supplement capsules.
  • Without a sufficiently blinded concurrent control, time effects, expectations, co-interventions and regression toward the mean can explain part of an apparent improvement.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial
Maria A Lizarralde-Iragorri et al. · Blood advances · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology